Hindustan Construction Company Ltd. Share Price

Daily Index View : NIFTY50 as on 07/10/2026

1. Market Trend PROBABILITY 🚨 Current Market Trend: Positive 🚀 10% 🔍 Key Level to Watch: 22569 🔄 Current Market Surface: The trend will stay Positive until the market stay above 22569 That’s 208 points away from the last day Closing Price of 22776 ATR 285 2. Demand & Supply PROBABILITY Force is Demand & Supply is High 15% Last 3 days market has been flatish compared to ATR, so demand has very strong firepower — it just needs sentiment support 06 Oct 2026 FII Cash-net (Buy/sell) DII Cash- net (BUY/SELL) -2,961 +5,088.92 3. Reflexivity PROBABILITY First Half is Supportive to Bullish Momentum for at least first half 10% Last day market rallied Intraday more than the 8-day average ATR, so it should keep its momentum intact in the first half 4. Social Proof (Global) PROBABILITY Dow Jones (Last day close) 48185 Up/Donw by 77 -19% Dow jones future (live) 51,762 Up/Donw by -54 Hang seng (Live) 24281 Up/Donw by -140 Nikki 225 (Live) 70074 Up/Donw by -610 Sentiments: Dow Jones Futures is Trading Flat to Negative & HANG SENG Index is trading Flat to Negative Today, global markets are neutral to slightly positive, and the Indian market has no strong directional bias

“Why Support and Resistance Need Context”

Support and resistance are important areas where price may experience a change in behavior. However, these levels should not be treated as exact points where price must always reverse. Market conditions, momentum and previous price reactions can influence how effectively a level holds. A strong level becomes more meaningful when price has reacted around the area multiple times or when it aligns with broader market structure. Traders can also observe whether price approaches the level with increasing or decreasing momentum. The reaction after reaching the area is often more informative than the level itself. A clear rejection, breakout or consolidation can provide additional evidence about the market’s next potential behavior. Learning: Support and resistance provide context, but price reaction and confirmation determine how useful the level becomes.

Dr. Reddy's Laboratories launches NIVORZ in India

Dr. Reddy's Laboratories has launched ‘NIVORZ’ (Nivolumab Biosimilar) in India. NIVORZ is a biosimilar to Opdivo (nivolumab). Developed and manufactured entirely in-house at the company’s biologics facility in Bachupally, Hyderabad, it reflects the company’s end-to-end capabilities across the biosimilar value chain, from development through commercialization. The launch of NIVORZ further strengthens the company's oncology portfolio and expands its presence in immuno-oncology. The Immuno-Oncology market in India is estimated at around Rs 3,900 crore in 2025 and is predominantly driven by checkpoint inhibitors such as nivolumab, pembrolizumab and toripalimab. Access to immuno-oncology therapies remains a challenge for many patients due to the cost and duration of treatment. Through NIVORZ, the company aims to broaden access to high-quality nivolumab therapy with an affordable biosimilar option for eligible patients. NIVORZ (Nivolumab) is one of the immunotherapy agents with the broadest range of approved indications in oncology in India, including Metastatic Non-Small Cell Lung Cancer (NSCLC), Renal Cell Carcinoma (RCC), Squamous Cell Carcinoma of the Head and Neck (SCCHN), Melanoma, Classical Hodgkin Lymphoma (cHL), Urothelial Carcinoma (UC), Colorectal Cancer (CRC), Esophageal squamous cell carcinoma (ESCC), Gastric Cancer, Gastroesophageal Junction Cancer and Esophageal Adenocarcinoma (GC, GEJC or EAC), Adjuvant treatment of Resected Esophageal or Gastroesophageal Junction Cancer (EC or GEJC), Malignant Pleural Mesothelioma (MPM) and Hepatocellular Carcinoma (HCC). Together, these approved indications span early-stage, locally advanced, recurrent, and metastatic disease settings across both solid and hematological malignancies.

HINDUSTAN CONSTRUCTION COMPANY ; SECURES ₹524 CR NHPC CONTRACT IN J&K 🏗️⚡️

HINDUSTAN CONSTRUCTION COMPANY ; SECURES ₹524 CR NHPC CONTRACT IN J&K 🏗️⚡️

India Aims to Deploy Five Small Modular Nuclear Reactors by 2033

India is ramping up its nuclear energy footprint by planning to deploy five indigenous Small Modular Reactors (SMRs) by 2033. To accelerate this transition, the enactment of the SHANTI Act, 2025 has officially opened the nuclear energy domain to private sector investment and technological collaboration. Key developments led by the Bhabha Atomic Research Centre (BARC) include a 220 MW Bharat Small Modular Reactor, a 55 MW SMR, and a High-Temperature Gas-Cooled Reactor specifically designed for clean hydrogen production, cementing the nation's indigenous capabilities in low-carbon energy technology. This initiative is a critical pillar of India's broader Nuclear Energy Mission, which targets an ambitious 100 GW of capacity by 2047. In the medium term, installed capacity is set to scale up from 8.78 GW to approximately 22 GW by 2031-32 as under-construction projects come online. By integrating private enterprise, advanced reactor designs, and localized manufacturing, India aims to bolster its energy security, meet expanding industrial demand, and solidify its position as a global leader in sustainable energy.